In type 2 diabetes patients with established CV disease,*
Choose JARDIANCE® to reduce the risk of CV death on top of standard of care1,2

 reduced cv death

Early and sustained reduction in CV death2-4

1. Jardiance® prescribing information, Boehringer-Ingelheim (India) Pvt Ltd. 2nd Feb, 2018.

2. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOM®). Cardiovasc Diabetol. 2014;13(102). doi:10.1186/1475-2840-13-102.

3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

4. Van de Borne, et al. Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOE®. Poster no. 1119 presented at: European Association for the Study of Diabetes. Annual Meeting; September 12-16, 2016; Munich, Germany.

(*Established CV Disease includes Coronary Artery Disease, or Peripheral Arterial Disease, or Myocardial Infarction, or Stroke)

Only OAD approved to reduce the risk of CV Death
in adult patients of T2DM with established CVD1

38%
Reduction in risk of

CV Death in T2D patients

with established CVD2

1. Jardiance® prescribing information. Boehringer-Ingelheim (India) Pvt Ltd. 2nd Feb, 2018.
2. Zinman B, et al. N Engl J Med. 2015;373(22):2117-28.

In a subgroup analysis* from EMPA-REG OUTCOME®
Reduction in risk of CV death for JARDIANCE® was independent of baseline HbA1c1,2

CONSISTENT ACROSS HbA1c

CV death
benefit outcome

 

CV death reduction was generally
consistent across baseline HbA1c3
Subgroup analysis included:
  • HbA1c <7%
  • HbA1c 7% to <8%
  • HbA1c 8% to <9%
  • HbA1c ≥9%

1. Jardiance® prescribing information, Boehringer-Ingelheim (India) Pvt Ltd. 2nd Feb, 2018.

2. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME®). Cardiovasc Diabetol. 2014;13(102). doi:10.1186/1475-2840-13-102.

3. Inzucchi SE, Fitchett D, Wanner C, et al. Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME®. Poster no. 916 presented at: 53rd Annual Meeting of the European Association for the Study of Diabetes; 11-15 September 2017; Lisbon, Portugal.

"A post-hoc analysis of data from the EMPA-REG OUTCOME® Trial by baseline HbA1c subgroups.
EMPA-REG OUTCOME® was not powered to show differences between subgroups.

Only Empagliflozin and Liraglutide have Level A evidence-based recommendation for reduction in major adverse CV events and/or CV death, in patients of T2DM with established CVD1

Recommendation for patients with T2DM and established atherosclerotic CVD1

1. Adapted from: American Diabetes Association. Standards of Medical Care in Diabetes 2018. Diabetes Care. 2018; 41(Suppl 1):s1 – s153